Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

This study aimed to evaluate the cost-effectiveness of osimertinib with gefitinib or erlotinib as first-line and sequential therapy for epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC) in China. The Markov model was used, and the study included 3 health st...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2019-02, Vol.41 (2), p.280-290
Hauptverfasser:	Cai, Hongfu, Zhang, Longfeng, Li, Na, Chen, Shen, Zheng, Bin, Yang, Jing, Weng, Lizhu, Liu, Mao-Bai
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides - economics Acrylamides - therapeutic use Aniline Compounds - economics Aniline Compounds - therapeutic use Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - economics Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy China Clinical trials Cost analysis Cost estimates Cost-Benefit Analysis cost-effectiveness Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - genetics Erlotinib Hydrochloride - economics Erlotinib Hydrochloride - therapeutic use FDA approval first-line treatment Gefitinib Gefitinib - economics Gefitinib - therapeutic use Growth factors Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - economics Lung Neoplasms - genetics Markov chains Metastases Metastasis Mutation Non-small cell lung carcinoma NSCLC osimertinib Patients Probability Protein Kinase Inhibitors - economics Protein Kinase Inhibitors - therapeutic use Sensitivity analysis Software Stability analysis Strategy Targeted cancer therapy Transition probabilities
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!